Escherichia coli-Based Cell-Free Protein Synthesis for Iterative Design of Tandem-Core Virus-Like Particles
Open Access
- 25 February 2021
- Vol. 9 (3), 193
- https://doi.org/10.3390/vaccines9030193
Abstract
Tandem-core hepatitis B core antigen (HBcAg) virus-like particles (VLPs), in which two HBcAg monomers are joined together by a peptide linker, can be used to display two different antigens on the VLP surface. We produced universal influenza vaccine candidates that use this scaffold in an Escherichia coli-based cell-free protein synthesis (CFPS) platform. We then used the CFPS system to rapidly test modifications to the arginine-rich region typically found in wild-type HBcAg, the peptide linkers around the influenza antigen inserts, and the plasmid vector backbone to improve titer and quality. Using a minimal plasmid vector backbone designed for CFPS improved titers by at least 1.4-fold over the original constructs. When the linker lengths for the influenza inserts were more consistent in length and a greater variety of codons for glycine and serine were utilized, titers were further increased to over 70 μg/mL (4.0-fold greater than the original construct) and the presence of lower molecular weight product-related impurities was significantly reduced, although improvements in particle assembly were not seen. Furthermore, any constructs with the C-terminal arginine-rich region removed resulted in asymmetric particles of poor quality. This demonstrates the potential for CFPS as a screening platform for VLPs.Funding Information
- Engineering and Physical Sciences Research Council (EP/P006485/1)
This publication has 33 references indexed in Scilit:
- Synthesis of encephalomyocarditis virus in a cell-free system: from DNA to RNA virus in one tubeBiotechnology Letters, 2011
- Modeling the competition between aggregation and self-assembly during virus-like particle processingBiotechnology & Bioengineering, 2010
- Internal Core Protein Cleavage Leaves the Hepatitis B Virus Capsid Intact and Enhances Its Capacity for Surface Display of Heterologous Whole Chain ProteinsOnline Journal of Public Health Informatics, 2008
- Escherichia coli‐based cell‐free synthesis of virus‐like particlesBiotechnology & Bioengineering, 2007
- Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancerExpert Opinion on Biological Therapy, 2007
- Towards the preparative and large-scale precision manufacture of virus-like particlesTrends in Biotechnology, 2005
- A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicityEuropean Journal of Immunology, 2005
- Production of recombinant proteins in Escherichia coliGenetics and Molecular Biology, 2004
- Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2Vaccine, 2003
- The Influence of Antigen Organization on B Cell ResponsivenessScience, 1993